Charles River Laboratories International, Inc. (CRL)
NYSE • Healthcare
Last close at October 23, 2026 at 20:00 UTC
Metrics Over Time
Where the Money Goes
Q2 2026Fundamentals & Financials
TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.
Income Statement
Balance Sheet
Financial Highlights
Dividends History
Split History
Earnings
Nov 4
in 10 daysQ4 2026% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS
Charles River Laboratories International beat expectations on both the top and bottom line in the second fiscal quarter of 2026, based on preliminary results reported Aug. 5. Revenue fell 3% to about $1.0 billion from $1.03 billion a year ago, but still came in above the $977.2 million estimate by 2.8%, while adjusted EPS of $3.02 topped the $2.77 consensus by 9% and was down 3% from $3.12 a year earlier. Operating income of about $119.9 million left operating margin near 12%, and operating cash flow was $179.7 million as the company repurchased about $115.6 million of stock. Consensus for the next period calls for EPS of $3.05 on revenue of $941.8 million.
Next report — what to expect
Charles River Laboratories International, Inc. (CRL) reports on November 4, 2026. Wall Street looks for EPS of $2.97 on revenue of $959.0 million. For trailing context, revenue declined -2.7% year over year last quarter. CRL has beaten EPS in 8 of 8 most recent quarters; focus on revenue and margin commentary versus expectations.
About Charles River Laboratories International, Inc.
Charles River Laboratories International, Inc. is a healthcare research-services company listed on the NYSE under CRL that supports pharmaceutical and biotechnology customers across preclinical drug development, laboratory testing, and research model supply. Its operations produced $4.0 billion of revenue in FY2025.
Today's Snapshot
CRL closed 1.6% above yesterday's close, outperforming a weaker sector. Volume was about two-thirds of its usual level. Charles River teamed with Labcorp, a laboratory company, and the FDA, a U.S. regulator, to validate new drug-safety tests.
Trading Volume
Below 10d avg (1.2M)
694.1K
vs S&P 500 Today
Outperforming Market
+2.17%
Updated: October 23, 2026 at 20:15 UTC
Technical Indicators
All signalsHide signals
- EMA (5 indicators)$232.88 - $321.26Buy
- RSI (14)73.18Sell
- Stochastic %K (14, 3, 3)88.61Sell
- MACD Level (12, 26)12.72Buy
Peers & Related Assets
Get premium market insights delivered directly to your inbox.